Combination use of platelets and recombinant activated factor VII for increased hemostasis during acute type a dissection operations

Journal of Cardiothoracic Surgery

Rihao Xu¹  Zijian Wang²  Ning Dong³  Liang Zhang¹  Guojia Ma⁵  Chengluan Xuan⁴  Wen Yan¹ 

[1] Department of Cardiovascular Surgery, Second Hospital of Jilin University, Jilin University, Changchun 130041, Jilin, China;Internal Medicine, Xiamen174 Hospital, Xiamen 361000, Fujian, China;The emergency department of the No.1 hospital of Jilin University, Jilin University, Changchun 130021, Jilin, China;Department of Anesthesiology, First Medical Hospital of Jilin University, Changchun 130021, Jilin, China;Department of Plant Pathology, North Dakota State University, Fargo 58102, ND, USA

关键词: Hemostatic strategy;    Acute type A dissection;    Recombinant activated factor VII (rFVIIa);    Platelets;   

Others  :  1152118
DOI  :  10.1186/s13019-014-0156-y

 received in 2014-04-10, accepted in 2014-08-25,  发布年份 2014

【 摘 要 】

Background

Refractory blood loss is a common problem in surgeries for acute type A aortic dissections. Significant evidence has supported the benefit of using recombinant activated factor VII (rFVIIa) to control of intractable bleeding in patients after cardiac surgery. In this prospective clinical study, we present a novel method to achieve intraoperative hemostasis by using a combination of platelets and rFVIIa during operations for acute type A aortic dissections.

Methods

Between May 2009 and August 2012, 71 patients with acute type A dissections who underwent emergency surgery were prospectively included and allocated to one of the following two intervention groups for hemostasis: 3 units platelets combined with 2.4 mg rFVIIa (n?=?25), and conventional methods (n?=?46).

Results

The patients who received the combination of platelets and rFVIIa required fewer transfusions of red blood cells (6.2?±?3.1 units vs 9.8?±?2.8 units; p?p?p?p?p?

Conclusions

Using a combination of platelets and rFVIIa is an effective strategy for achieving hemostasis during acute type A dissection surgery. This hemostatic strategy does not appear to be associated with an increase in postoperative adverse events.

【 授权许可】

   
2014 Yan et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Ramanath VS, Oh JK, Sundt TM 3rd, Eagle KA: Acute aortic syndromes and thoracic aortic aneurysm. Mayo Clin Proc 2009, 84:465-481.
• [2]Von Heymann C, Redlich U, Jain U, Kastrup M, Schroeder T, Grosse J, Ziemer S, Koscielny J, Konertz WF, Wernecke KD, Spies C: Recombinant activated factor VII for refractory bleeding after cardiac surgery- A retrospective analysis of safety and efficacy. Crit Care Med 2005, 33:2241-2246.
• [3]Tritapepe L, De Santis V, Vitale D, Nencini C, Pellegrini F, Landoni G, Toscano F, Miraldi F, Pietropaoli P: Recombinant activated factor VII for refractory bleeding after acute aortic dissection surgery: a propensity score analysis. Crit Care Med 2007, 35:1685-1690.
• [4]Gelsomino S, Lorusso R, Romagnoli S, Bevilacqua S, De Cicco G, Bille G, Gensini GF: Treatment of refractory bleeding after cardiac operations with low-dose recombinant activated factor VII (NovoSeven): a propensity score analysis. Eur J Cardiothorac Sur 2008, 33:64-71.
• [5]Masud F, Bostan F, Chi E, Pass SE, Samir H, Stuebing K, Liebl MG: Recombinant factor VIIa treatment of severe bleeding in cardiac surgery patients: a retrospective analysis of dosing, efficacy, and safety outcomes. J Cardiothorac Vasc Anesth 2009, 23:28-33.
• [6]Levi M, Peters M, Buller HR: Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systemic review. Crit Care Med 2005, 33:883-890.
• [7]Warren O, Mandal K, Hadjianastassiou V, Knowlton L, Panesar S, John KJ: Recombinant activated factor VII in cardiac surgery: a systematic review. Ann Thorac Surg 2007, 83:707-714.
• [8]Duran M, Gunebakmaz O, Uysal OK, Ocak A, Yilmaz Y, Arinc H, Eryol NK, Ergin A, Kaya MG: The relation between mean platelet volume and coronary collateral vessels in patients with acute coronary syndromes. J Cardiol 2013, 61(4):295-298.
• [9]Balasubramanian V, Grabowski E, Bini A, Nemerson Y: Platelets, circulating tissue factor, and fibrin colocalize in ex vivo thrombi: real-time fluorescence images of thrombus formation and propagation under defined flow conditions. Blood 2002, 100:2787-2792.
• [10]Lizhong Sun MD, RuiDong Qi MD, Qian Chang MD, JunMing Zhu MD, YongMin Liu MD, ChunTao Yu MD, HaiTao Zhang MD, Bin Lv MD, Jun Zheng MD, Liangxin Tian MD, JinGuo Lu MD: Surgery for acute a dissection with the tear in the descending Aorta using a stented elephant trunk procedure. Ann Thorac Surg 2009, 87:1177-1181.
• [11]Lizhong S, RuiDong Q, JunMing Z, YongMin L, Qian C, Jun Z: Repair of Acute Type A Dissection: Our Experiences and Results. Ann Thorac Surg 2011, 91:1147-1153.
• [12]Dipros P, Herbertson MJ, O¿Shaughnessy D, Gill RS: Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: Randomized double-blind placebo-controlled pilot study. Br J Anaesth 2005, 95(5):596-602.
• [13]Welsby J, Monroe DM, Lawson JH, Hoffmann M: Recombinant activated factor VII and the anaethetist. Anaesthesia 2005, 60:1203-1212.
• [14]Willis C, Bird R, Mullany D, Cameron P, Philisps L: Use of rFVIIa for critical bleeding in cardiac surgery: dose variation and patient outcomes. Vox Sang 2010, 98:531-537.
• [15]Nicholas AD, Bhattacharya SD, Williams JB, Fosbol EL, Lockhart EL, Patel MB, Gaca JG, Welsby IJ, Hughes GC: Intraoperative use of low-dose recombinant activated factor VII during thoracic aortic operations. Ann Thorac Surg 2012, 93:1921-1929.
• [16]Hendrisks HG, Meijer K, De Wolf JT, Porte RJ, Klompmaker IJ, Lip H, Slooff MJ, Van der Meer J: Effects of recombinant activated factor VII on coagulation measured by thromboelastography in liver tansplatation. Blood Coagul Fibrinolysis 2002, 13:309-313.
• [17]Ponschab M, Landoni G, Biondi-Zoccai G, Bignami E, Frati E, Nicolotti D, Monaco F, Pappalardo F, Zangrillo A: Recombinant activated factor VII increases stroke in cardiac surgery: A meta-analysis. J Cardiothorac Vasc Anesth 2011, 25(5):804-810.
• [18]Butensa S, Brummel KE, Branda RF, Paradis SG, Mann KG: Mechanism of factor VIIA-dependent coagulation in hemophilia blood. Blood 2002, 99:923-930.
• [19]Elsherbiny IA, Shoukry A, Tahlawi MAE: Mean platelet volume and its relation to insulin resistance in non-diabetic patients with slow coronary flow. J Cardiol 2012, 59(2):176-181.
• [20]Ernofsson M, Thelin S, Siegbahn A: Monocyte tissue factor expression, cell activation, and thrombin formation during cardiopulmonary bypass: a clinical study. J Thorac Cardiovasc Surg 1997, 113:576-584.
• [21]Dietrich W, Spannagl M: Caveat against the use of activated recombinant factor VII for intractable bleeding in cardiac surgery. Anesth Analg 2002, 94:1369-1370.
• [22]Gill R, Herbertson M, Vuylsteke A, Olsen PS, Von Heymann C, Mythen M, Sellke F, Booth F, Schmidt TA: Safety and efficacy of recombinant activated factor VII a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery. Circulation 2009, 120:21-27.
• [23]Mitra B, Phillips I, Cameron PA, Billah B, Reid C: The safety of recombinant factor VIIa in cardiac surgery. Anaesh Inensive Care 2010, 38:671-677.
• [24]O¿Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM: Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006, 295:293-298.
• [25]Johnson SJ, Ross MB, Moores KG: Dosing factor VIIa(recombinant) in nonhemophiliac patients with bleeding after cardiac surgery. Am J Health Syst Pharm 2007, 64:1808-1812.